Nanosyrinx raises £6.2m to validate drug delivery platform
Coventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
Unilever licences Arzeda Inc.s enzyme technology
As part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Bio-Me raises NOK10m
Oslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
Novalis Biotech closes biotech fund at 25m
Cellink AB to take-over Discover Echo Inc
Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Rheincell set to be acquired by Catalent
Major CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.
Data protection rules may block medical progress
In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.
NeuVasQ Biotechnologies bags 20m in Series A financing
NeuVasQ Biotechnologies has raised 20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.
Coriolis Pharma expands its ATMP development facilities
Coriolis Pharma will launch operations at its currently expanded ATMP development facilities by Q4/2021.
BioverSys AG bags $15m CARB-X funding
CARB-X is funding Swiss pharma company BioVersys with $15.2m to develop a new class of antibiotics to treat infections caused by multidrug-resistant pathogens.